[68Ga]Ga-DOTA.SA.FAPi 的生物分布、药代动力学、剂量学及与 [18F]F-FDG PET/CT 在多种癌症中的头对头比较
该示踪剂在肝、肾、胰腺等有生理摄取,胰腺吸收剂量最高;对脑转移灶的靶/本底比值显著优于FDG,其余转移灶两者可比。
要点
- [68Ga]Ga-DOTA.SA.FAPi在肝、肾、胰腺、心脏内容物有生理摄取,胰腺吸收剂量最高。
- 对脑转移灶,该示踪剂SULpeak/正常脑比值中位59.3,显著高于FDG的1.5(P=0.028)。
- 除脑转移外,各转移灶的SULpeak与SULavg在两种示踪剂间无显著差异。
核心结论
- [68Ga]Ga-DOTA.SA.FAPi是FAPI类分子中有前景的替代示踪剂,在多种癌症诊断中表现与标准示踪剂[18F]F-FDG相当。
研究设计与样本
- 剂量学在3例患者中用[68Ga]Ga-DOTA.SA.FAPi系列时间点成像,以OLINDA/EXM 2.2软件计算吸收剂量。
- 摄取量化采用瘦体重校正的标准化摄取值(SUL)。
主要发现
- 肿瘤类型分布:乳腺癌37%、肺癌24%、头颈癌7.4%、其他组织学31.6%。
- [68Ga]Ga-DOTA.SA.FAPi靶病灶摄取在10分钟开始,延迟采集时间点未检出额外病灶。
- 基于患者的比较显示,原发灶、胸膜增厚、骨和肝转移及第二原发恶性肿瘤的检出完全一致。
- 不一致见于淋巴结(7.5%)、肺结节(5.6%)和脑转移(2%)的检出。
- 头颈癌在[68Ga]Ga-DOTA.SA.FAPi上SULpeak和SULavg最高,与[18F]F-FDG相近(SULpeak 15.4 vs 14.2,P=0.680;SULavg 8.3 vs 7.9,P=0.783)。
关键数值与推荐
- 胰腺是吸收剂量最高的器官,为5.46E-02 mSv/MBq。
- 脑转移灶与正常脑实质比值:SULpeak中位59.3(IQR 33.5-130.8)vs 1.5(1-2.3),P=0.028,[68Ga]Ga-DOTA.SA.FAPi显著更高。
- 肺癌两种示踪剂摄取最低(SULpeak 5.8 vs 7.4,P=0.238;SULavg 4.9 vs 5.3,P=0.313)。
- 除脑转移外,其他转移区域的SULpeak和SULavg在两种示踪剂间可比、无显著差异。
临床怎么用
- 可用于多种癌症的PET/CT显像评估,尤其脑转移灶因高靶/本底比值可能较FDG有优势。
- 判读时需注意肝、肾、胰腺、心脏内容物及泪腺、口腔黏膜、唾液腺、甲状腺的生理摄取。
- 注射后10分钟靶病灶即可见摄取,延迟显像未增加病灶检出。
局限性
- 剂量学仅基于3例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [68Ga]Ga-labeled fibroblast activation protein inhibitors ([68Ga]Ga-FAPi) have shown promising preclinical and clinical results in PET imaging. The present study aimed to evaluate the biodistribution, pharmacokinetics, and dosimetry of [68Ga]Ga-DOTA.SA.FAPi, another modified FAPi tracer, and performed a head-to-head comparison with [18F]F-FDG PET/CT scans in patients with various cancers. METHODS: In this prospective study, patients underwent both [18F]F-FDG and [68Ga]Ga-DOTA.SA.FAPi PET/CT scans 60 min post-injection (p.i.). Dosimetry studies were conducted in three patients using [68Ga]Ga-DOTA.SA.FAPi serial time-point imaging. The absorbed dose was calculated using OLINDA/EXM 2.2 software. Quantification of the uptake of the tracers was assessed using standardized uptake values corrected for lean body mass (SUL). RESULTS: Fifty-four patients (mean age; 48.4 years) with 14 types of cancers involving 37% breast, 24% lung, 7.4% head and neck (H&N), and remaining 31.6% patients with other histologies were evaluated prospectively. Physiological uptake of [68Ga]Ga-DOTA.SA.FAPi was observed in the liver, kidneys, pancreas, heart contents, and to a lesser extent in the lacrimals, oral mucosa, salivary glands, and thyroid glands. Uptake in the target lesions on [68Ga]Ga-DOTA.SA.FAPi scan was initiated at 10 min, and no additional lesions were detected in the delayed acquisition time points. The pancreas was the organ with the highest absorbed dose (5.46E-02 mSv/MBq). While the patient-based comparison between the radiotracers revealed complete concordance in the detection of primary, pleural thickening, bone and liver metastases, and second primary malignancy, discordant findings were observed in the detection of lymph node (7.5%), lung nodules (5.6%), and brain metastases (2%). According to the site of primary disease, patients with H&N cancers demonstrated the highest SULpeak and average (avg) values on [68Ga]Ga-DOTA.SA-FAPi which was similar to the values of [18F]F-FDG [(SULpeak: 15.4 vs. 14.2; P-0.680) (SULavg: 8.3 vs. 7.9; P-0.783)]. The lowest uptake was observed in lung cancers with both the radiotracers [(SULpeak: 5.8 vs. 7.4; P-0.238) (SULavg: 4.9 vs. 5.3; P-0.313)]. A significantly higher SULpeak and SULavg for brain metastases to normal brain parenchyma ratios were observed on [68Ga]Ga-DOTA.SA.FAPi in contrast to the [18F]F-FDG values {SULpeak: median: 59.3 (IQR: 33.5-130.8) versus 1.5 (1-2.3); P-0.028}. Except for brain metastases, comparable SULpeak and average values were noted between the radiotracers in all other regions of metastases with no significant difference. CONCLUSION: [68Ga]Ga-DOTA.SA.FAPi is a promising alternative among the FAPI class of molecules and performed well as compared to standard-of-care radiotracer [18F]F-FDG in the diagnosis of various cancers.
引用
- Ballal S, Yadav MP, Moon ES, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2020. PMID: 33244617. doi:10.1007/s00259-020-05132-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。